Moderna
42°21′48″N 71°05′28″W / 42.3633°N 71.091°W
Moderna headquarters in Cambridge, Massachusetts | |
| Formerly | ModeRNA Therapeutics (2010–2018) |
|---|---|
| Type | Public |
| |
| ISIN | US60770K1079 |
| Industry | Biotechnology |
| Founded | September 2010 |
| Founders | |
| Headquarters | 200 Technology Square Cambridge, Massachusetts, U.S. |
Key people |
|
| Products | |
| Revenue | US$19.26 billion (2022) |
| US$9.420 billion (2022) | |
| US$8.362 billion (2022) | |
| Total assets | US$25.86 billion (2022) |
| Total equity | US$19.12 billion (2022) |
| Owners |
|
Number of employees | 3,900 (2022) |
| Website | modernatx |
| Footnotes / references [1][2][3] | |
Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə)[4] is a pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response.[5][1] The company's name is derived from the terms "modified", "RNA", and "modern".[6][7][8]
The company's only commercial product is the Moderna COVID-19 vaccine, marketed as Spikevax. The company has 45 treatment and vaccine candidates, of which 38 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, respiratory syncytial virus, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines. The company's pipeline also includes a cell therapy-based treatment: a relaxin fusion protein being developed to treat acute decompensated heart failure. It also includes candidates that use OX40 ligand, interleukin 23, IL36G, and interleukin 12 for cancer immunotherapy, specifically treatment of breast cancer, urothelial carcinoma, lymphoma, and melanoma. Also being developed by Moderna is a regenerative medicine treatment that encodes vascular endothelial growth factor A to stimulate blood vessel growth for patients with myocardial ischemia.[1]
History
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan.[9] Stéphane Bancel, the current CEO, was appointed as CEO in 2011.[6][10] Between 2011 and 2017, Moderna raised $2 billion in venture capital funding.[7][8]
Product development
In 2013, the company formed a partnership with AstraZeneca to develop treatments for cardiovascular, metabolic, and renal diseases, as well as cancer. In January 2014, the company entered an agreement with Alexion Pharmaceuticals to develop treatments against ten diseases.[11] On January 14, 2014, Moderna announced the creation of its first spinoff company, Onkaido Therapeutics, to focus "exclusively on developing mRNA-based oncology treatments."[12][13] It launched its second spinoff, Valera, in January 2015, with a focus on "viral, bacterial and parasitic infectious diseases."[14][15] Employees of Valera and Moderna would go on to develop an mRNA vaccine candidate against Zika virus infection.[16] Another spinoff, Elpidera, was announced in May 2015 to continue work on RNA therapies advancing Moderna's work with Alexion.[17][18]
In 2015, the company formed a partnership with Merck & Co. to develop treatments for cancer, and in 2016 the company formed a partnership with Vertex Pharmaceuticals to develop treatments for cystic fibrosis.[10][19][20][21] In January 2016, the Bill & Melinda Gates Foundation committed to provide at least $20 million in grant funding to the company.[1]
In July 2018, the company opened a 200,000 square foot facility in Norwood, Massachusetts for manufacturing, preclinical and clinical work.[6][22] In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share.[23][24]
The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019.[6] In 2023, Moderna acquired OriCiro Genomics, a Japanese manufacturer of genetic engineering tools, in its first acquisition.[25]
COVID-19 vaccine
From 2020 to 2021, Moderna received $955 million from Operation Warp Speed to accelerate development of its COVID-19 vaccine, with $4.9 billion committed in total for producing 300 million vaccine doses.[26][27]
In March 2020, the Food and Drug Administration approved clinical trials for the Moderna COVID‑19 vaccine candidate, and in December, the vaccine, mRNA-1273, was issued an emergency use authorization in the United States.[28][29] In 2022, it gained FDA approval both for the monovalent vaccine, Spikevax, and a bivalent booster.[30]
In April 2022, Moderna announced plans to build a $180 million vaccine factory in Montreal, forming a 10-year partnership with the Government of Canada, Quebec, and McGill University to produce 100 million Spikevax doses annually and expand vaccine research capabilities.[31]
In August 2022, Moderna sued Pfizer and BioNTech in both Massachusetts and Germany, alleging that the Pfizer–BioNTech COVID-19 vaccine violates the patent on Moderna's mRNA vaccine technology.[32]
In 2023, the company agreed to pay $400 million to the National Institutes of Health, Dartmouth College, and Scripps Research to settle a dispute over the rights to a chemical technique that was used in the vaccine.[33]
Financial data
See also
References
- ^ a b c d e f g h "Moderna, Inc., 2022, Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 24, 2023.
- ^ "Moderna, Inc. Schedule 14A 2021 Proxy Statement". U.S. Securities and Exchange Commission. March 9, 2022.
- ^ "Key Facts". Moderna.
- ^ Moderna (October 23, 2019). mRNA-3704 and Methylmalonic Acidemia (video) – via YouTube.
- ^ Park KS, Sun X, Aikins ME, Moon JJ (December 2020). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews. 169: 137–51. doi:10.1016/j.addr.2020.12.008. PMC 7744276. PMID 33340620.
- ^ a b c d "Moderna, Our story; Our big moments". Moderna, Inc. 2023. Retrieved February 10, 2023.
- ^ a b Garde, Damian; Saltzman, Jonathan (November 10, 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. from the original on November 10, 2020.
- ^ a b Servick, Kelly (March 25, 2020). "This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines (from the original, 1 February 2017)". Science. doi:10.1126/science.aal0686. S2CID 241466550.
- ^ Elton, Catherine (March 2013). "The NEXT Next Big Thing". Boston Magazine. from the original on November 16, 2020.
- ^ a b Garde, Damien (September 13, 2016). "Ego, ambition, and turmoil: Inside one of biotech's most secretive startups". Stat. from the original on November 16, 2020.
- ^ Reidy, Chris (January 13, 2014). "Alexion, Moderna announce agreement to develop messenger RNA therapeutics". Boston Globe Media Partners. Archived from the original on July 2, 2021. Retrieved June 5, 2023.
- ^ Favorito, Maria (January 14, 2014). . Moderna Therapeutics. Archived from the original on November 20, 2016. Retrieved June 5, 2023.
{{cite web}}: CS1 maint: unfit URL (link) - ^ Gormley, Brian (January 15, 2014). . Wall Street Journal. ISSN 0099-9660. Archived from the original on June 5, 2023. Retrieved June 5, 2023.
- ^ Favorito, Maria (January 8, 2015). . Moderna Therapeutics. Archived from the original on November 19, 2016. Retrieved June 5, 2023.
{{cite web}}: CS1 maint: unfit URL (link) - ^ "Moderna Launches New Venture Valera LLC for Infectious Diseases". Bionity. January 12, 2015. Archived from the original on June 5, 2023. Retrieved June 5, 2023.
- ^ Richner, Justin M.; Himansu, Sunny; Dowd, Kimberly A.; Butler, Scott L.; Salazar, Vanessa; Fox, Julie M.; Julander, Justin G.; Tang, William W.; Shresta, Sujan; Pierson, Theodore C.; Ciaramella, Giuseppe; Diamond, Michael S. (February 17, 2017). "Modified mRNA Vaccines Protect against Zika Virus Infection". Cell. 168 (6): 1114–1125.e10. doi:10.1016/j.cell.2017.02.017. ISSN 0092-8674. PMC 5388441. PMID 28222903.
- ^ Guisbond, Amanda (May 12, 2015). . Moderna Therapeutics. Archived from the original on October 12, 2016. Retrieved June 5, 2023.
{{cite web}}: CS1 maint: unfit URL (link) - ^ Tirrell, Meg (May 12, 2015). "The biotech targeting personalized medicine". CNBC. Archived from the original on April 10, 2021. Retrieved June 5, 2023.
- ^ Weisman, Robert (March 21, 2013). "Moderna in line for $240m licensing deal". The Boston Globe. from the original on November 16, 2020.
- ^ "Moderna: Strategic collaborators". Moderna, Inc. 2023. Retrieved February 11, 2023.
- ^ "Vertex and Moderna hammer out $315 million+ deal to treat cystic fibrosis using mRNA technology". BioSpace. July 6, 2016. Retrieved February 11, 2023.
- ^ DeAngelis, Allison (July 17, 2018). "Moderna's $110M Norwood site built with expansion hopes". American City Business Journals.
- ^ Mukherjee, Sy (December 8, 2018). "Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future". Fortune. from the original on November 16, 2020.
- ^ Ramsey, Lydia (December 7, 2018). "Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion". Business Insider. from the original on November 16, 2020.
- ^ Hayden Schmidt (January 5, 2023). "Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition". PharmaNews Intelligence. Retrieved February 12, 2023.
- ^ Valverde, Miriam (November 19, 2020). "How Pfizer's and Moderna's COVID-19 vaccines are tied to Operation Warp Speed". PolitiFact. Retrieved February 12, 2023.
- ^ Siddalingaiah, Simi V. (March 1, 2021). "Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials". Congressional Research Service, United States Government. Retrieved February 12, 2023.
- ^ "Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine". National Institutes of Health. December 18, 2020.
- ^ Ledford, Heidi (December 18, 2020). "Moderna COVID vaccine becomes second to get US authorization". Nature. doi:10.1038/d41586-020-03593-7. PMID 33340017. S2CID 243212854. Retrieved February 12, 2023.
- ^ "Moderna COVID-19 vaccines". US Food and Drug Administration. December 15, 2022. Retrieved February 11, 2023.
- ^ "Moderna facility in Montreal area expected to produce 100 million vaccine doses by 2024". CBC News. April 29, 2022.
- ^ Robbins, Rebecca; Gross, Jenny (August 26, 2022). "Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology". The New York Times. ISSN 0362-4331. Retrieved August 26, 2022.
- ^ Mueller, Benjamin (February 23, 2023). "After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique". The New York Times.
External links
- Official website
- Business data for Moderna, Inc.:
- Bloomberg
- Reuters
- SEC filings
- Yahoo!